Lukas Smolej, MD, PhD, Charles University, Hradec Králové, Czech Republic, comments on the possibility of combining venetoclax with BTK inhibitors or monoclonal antibodies in chronic lymphocytic leukemia (CLL), discussing the efficacy and toxicity of these treatment regimens and their place in the frontline and relapsed/refractory (R/R) setting. This interview took place at the 2022 European Research Initiative on CLL (ERIC) Meeting.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.